Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience

Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 × 10(9)/l at baseline co...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, Simone, Rigacci, Luigi, Carrai, Valentina, Alterini, Renato, Fjerza, Rajmonda, Bosi, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395680/
https://www.ncbi.nlm.nih.gov/pubmed/22811793
http://dx.doi.org/10.4084/MJHID.2012.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395680/
https://www.ncbi.nlm.nih.gov/pubmed/22811793
http://dx.doi.org/10.4084/MJHID.2012.044

Ejemplares similares